Moog Announces Medical Devices Acquisition

    EAST AURORA, N.Y., Dec. 30 /PRNewswire-FirstCall/ -- Moog Inc. (NYSE:
MOG.A and MOG.B) announced today that it has acquired 100% of the stock of
AITECS Medical UAB, a Lithuanian-based manufacturer of syringe-style
infusion therapy pumps, for euro 15 million ($21 million), paid in cash.
Founded in 1993, AITECS has a product portfolio that includes pumps for
general hospital use, operating rooms and patient controlled analgesia.

    The acquisition complements Moog's current medical devices product
line. "This acquisition is a great fit while broadening our product
offering and geographic presence in the infusion therapy market," said
Martin Berardi, President of the Medical Devices Group of Moog.

    Sales for AITECS will be approximately euro 4 million ($6 million) for
the balance of Moog's fiscal year 2009. This acquisition is expected to be
neutral to Moog's earnings per share for the year ending October 3, 2009
due to first year purchase accounting adjustments.

    Moog Inc. is a worldwide designer, manufacturer, and integrator of
precision control components and systems. Moog's high-performance systems
control military and commercial aircraft, satellites and space vehicles,
launch vehicles, missiles, automated industrial machinery, marine and
medical equipment. Additional information can be found at http://www.moog.com.

    Cautionary Statement

    Information included herein or incorporated by reference that does not
consist of historical facts, including statements accompanied by or
containing words such as "may," "will," "should," "believes," "expects,"
"expected," "intends," "plans," "projects," "estimates," "predicts,"
"potential," "outlook," "forecast," "anticipates," "presume" and "assume,"
are forward-looking statements. Such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements are not guarantees of future
performance and are subject to several factors, risks and uncertainties,
the impact or occurrence of which could cause actual results to differ
materially from the expected results described in the forward-looking
statements. These important factors, risks and uncertainties include (i)
fluctuations in general business cycles for commercial aircraft, military
aircraft, space and defense products, industrial capital goods and medical
devices, (ii) our dependence on government contracts that may not be fully
funded or may be terminated, (iii) our dependence on certain major
customers, such as The Boeing Company, for a significant percentage of our
sales, (iv) the possibility that the demand for our products may be reduced
if we are unable to adapt to technological change, (v) intense competition
which may require us to lower prices or offer more favorable terms of sale,
(vi) our significant indebtedness which could limit our operational and
financial flexibility, (vii) the possibility that new product and research
and development efforts may not be successful which could reduce our sales
and profits, (viii) increased cash funding requirements for pension plans,
which could occur in future years based on assumptions used for our defined
benefit pension plans, including returns on plan assets and discount rates,
(ix) a write-off of all or part of our goodwill, which could adversely
affect our operating results and net worth and cause us to violate
covenants in our bank agreements, (x) the potential for substantial fines
and penalties or suspension or debarment from future contracts in the event
we do not comply with regulations relating to defense industry contracting,
(xi) the potential for cost overruns on development jobs and fixed price
contracts and the risk that actual results may differ from estimates used
in contract accounting, (xii) the possibility that our subcontractors may
fail to perform their contractual obligations, which may adversely affect
our contract performance and our ability to obtain future business, (xiii)
our ability to successfully identify and consummate acquisitions, and
integrate the acquired businesses and the risks associated with
acquisitions, including that the acquired businesses do not perform in
accordance with our expectations, and that we assume unknown liabilities in
connection with the acquired businesses for which we are not indemnified,
(xiv) our dependence on our management team and key personnel, (xv) the
possibility of a catastrophic loss of one or more of our manufacturing
facilities, (xvi) the possibility that future terror attacks, war or other
civil disturbances could negatively impact our business, (xvii) that our
operations in foreign countries could expose us to political risks and
adverse changes in local, legal, tax and regulatory schemes, (xviii) the
possibility that government regulation could limit our ability to sell our
products outside the United States, (xix) product quality or patient safety
issues with respect to our medical devices business that could lead to
product recalls, withdrawal from certain markets, delays in the
introduction of new products, sanctions, litigation, declining sales or
actions of regulatory bodies and government authorities, (xx) the impact of
product liability claims related to our products used in applications where
failure can result in significant property damage, injury or death and in
damage to our reputation, (xxi) the possibility that litigation may result
unfavorably to us, (xxii) our ability to adequately enforce our
intellectual property rights and the possibility that third parties will
assert intellectual property rights that prevent or restrict our ability to
manufacture, sell, distribute or use our products or technology, (xxiii)
foreign currency fluctuations in those countries in which we do business
and other risks associated with international operations, (xxiv) the cost
of compliance with environmental laws, (xxv) the risk of losses resulting
from maintaining significant amounts of cash and cash equivalents at
financial institutions that are in excess of amounts insured by
governments, (xxvi) the inability to utilize amounts available to us under
our credit facilities given uncertainties in the credit markets and (xxvii)
our customer's inability to pay us due to adverse economic conditions or
their inability to access available credit. The factors identified above
are not exhaustive. New factors, risks and uncertainties may emerge from
time to time that may affect the forward-looking statements made herein.
Given these factors, risks and uncertainties, investors should not place
undue reliance on forward-looking statements as predictive of future
results. We disclaim any obligation to update the forward-looking
statements made in this report.